Galapagos and AstraZeneca enter new drug discovery collaboration

23-Apr-2007

Galapagos NV announced that its service division, BioFocus DPI, has entered into a new drug discovery collaboration with AstraZeneca. This is the second program between the two companies under an agreement signed in August 2006. In this new collaboration, BioFocus DPI will perform medicinal chemistry, computational chemistry and supporting biology and ADMET services for an AstraZeneca drug discovery program. Total contract value for Galapagos is EUR620,000.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance